{
    "clinical_study": {
        "@rank": "82284", 
        "arm_group": {
            "arm_group_label": "Antithrombin-III Human 500IU", 
            "arm_group_type": "Experimental", 
            "description": "Freeze-dried Concentrated Human Antithrombin \u2162 500 IU\nUnits required (IU)/kg = 50 + [(desired-baseline AT-III level) x weight (kg) / 1.4]"
        }, 
        "brief_summary": {
            "textblock": "To evaluate efficacy and safety of AT-III treatment in patients with hepatic veno-occlusive\n      diseases following hematopoietic stem cell transplantation."
        }, 
        "brief_title": "Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatic Veno-Occlusive Disease", 
        "condition_browse": {
            "mesh_term": [
                "Hepatic Veno-Occlusive Disease", 
                "Budd-Chiari Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with hepatic veno-occlusive disease after hematopoietic stem cell\n             transplantation. The following criteria will be used.\n\n               1. Two of the following\n\n                    -  Serum total bilirubin > 2.0 mg/dL\n\n                    -  Hepatomegaly or right upper quadrant pain of liver origin\n\n                    -  Unexplained weight gain of>2% over baseline because of fluid accumulation\n\n               2. Patients with pathologic diagnosis.\n\n          2. Patients with informed consent\n\n        Exclusion Criteria:\n\n          1. Pregnant or nursing women.\n\n          2. Malignant or nonmalignant illness that is uncontrolled or whose control may be\n             jeopardized by complications of study therapy.\n\n          3. Psychiatric disorder that would preclude compliance.\n\n          4. Patients who, in the opinion of the investigator, may not be able to comply with the\n             safety monitoring requirements of the study.\n\n          5. History of anaphylactic reaction to the study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886248", 
            "org_study_id": "Antithrombin-III"
        }, 
        "intervention": {
            "arm_group_label": "Antithrombin-III Human 500IU", 
            "intervention_name": "Freeze-dried Concentrated Human Antithrombin \u2162 500 IU", 
            "intervention_type": "Drug", 
            "other_name": "Antithrombin-III Human 500IU"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antithrombins", 
                "Antithrombin III", 
                "Antithrombin Proteins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "hepatic veno-occlusive disease after hematopoietic stem cell transplantation", 
        "lastchanged_date": "November 17, 2013", 
        "location": {
            "contact": {
                "email": "kanghj@snu.ac.kr", 
                "last_name": "Hyoung Jin Kang, M.D, Ph.D", 
                "phone": "82 2 2072 3304"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Chongno-gu"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation", 
        "overall_contact": {
            "email": "kanghj@snu.ac.kr", 
            "last_name": "Hyoung Jin Kang, MD, Ph.D", 
            "phone": "82 2 2072 3304"
        }, 
        "overall_contact_backup": {
            "email": "agnesjw@hanmail.net", 
            "last_name": "Ji Won Lee, MD", 
            "phone": "82 2 2072 4192"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Hyoung Jin Kang, MD, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "AT-III level before 5th dose of AT-III", 
            "safety_issue": "No", 
            "time_frame": "up to 14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886248"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AT-III level before 9th dose", 
            "safety_issue": "No", 
            "time_frame": "up to 14 days"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}